113 related articles for article (PubMed ID: 16118401)
1. Hormone-refractory prostate cancer in the Lobund-Wistar rat.
Pollard M; Suckow MA
Exp Biol Med (Maywood); 2005 Sep; 230(8):520-6. PubMed ID: 16118401
[TBL] [Abstract][Full Text] [Related]
2. Dietary prevention of hormone refractory prostate cancer in Lobund-Wistar rats: a review of studies in a relevant animal model.
Pollard M; Suckow MA
Comp Med; 2006 Dec; 56(6):461-7. PubMed ID: 17219775
[TBL] [Abstract][Full Text] [Related]
3. Prevention of prostate-related cancers in Lobund-Wistar rats.
Pollard M
Prostate; 1999 Jun; 39(4):305-9. PubMed ID: 10344221
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of Lobund-Wistar x Copenhagen hybrid rats to autochthonous prostate carcinogenesis.
Suckow MA; Wolter W; Pollard M
Prostate; 2005 Jul; 64(2):203-8. PubMed ID: 15712219
[TBL] [Abstract][Full Text] [Related]
5. PAIII prostate tumors express prostate specific antigen (PSA) in Lobund-Wistar rats.
Suckow MA; Wheeler J; Yan M
Can J Vet Res; 2009 Jan; 73(1):39-41. PubMed ID: 19337394
[TBL] [Abstract][Full Text] [Related]
6. The Lobund-Wistar rat model of prostate cancer.
Pollard M
J Cell Biochem Suppl; 1992; 16H():84-8. PubMed ID: 1289678
[TBL] [Abstract][Full Text] [Related]
7. Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer.
Sinha I; Null K; Wolter W; Suckow MA; King T; Pinto JT; Sinha R
Int J Cancer; 2012 Mar; 130(6):1430-9. PubMed ID: 21500193
[TBL] [Abstract][Full Text] [Related]
8. Diet and the duration of testosterone-dependent prostate cancer in Lobund-Wistar rats.
Pollard M; Wolter W; Sun L
Cancer Lett; 2001 Nov; 173(2):127-31. PubMed ID: 11597786
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.
Desai D; Sinha I; Null K; Wolter W; Suckow MA; King T; Amin S; Sinha R
Int J Cancer; 2010 Jul; 127(1):230-8. PubMed ID: 19918950
[TBL] [Abstract][Full Text] [Related]
10. Early manifestations of induced prostate tumors in Lobund-Wistar rats.
Pollard M; Luckert PH
Cancer Lett; 1992 Dec; 67(2-3):113-6. PubMed ID: 1483259
[TBL] [Abstract][Full Text] [Related]
11. Prostatic localization of spontaneous early invasive carcinoma in Lobund-Wistar rats.
Pugh TD; Chang C; Uemura H; Weindruch R
Cancer Res; 1994 Nov; 54(22):5766-70. PubMed ID: 7525050
[TBL] [Abstract][Full Text] [Related]
12. Treatment options in hormone-refractory prostate cancer: current and future approaches.
Harris KA; Reese DM
Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
[TBL] [Abstract][Full Text] [Related]
13. Regulation of androgen receptor signaling in prostate cancer.
Dehm SM; Tindall DJ
Expert Rev Anticancer Ther; 2005 Feb; 5(1):63-74. PubMed ID: 15757439
[TBL] [Abstract][Full Text] [Related]
14. High incidence and histogenesis of seminal vesicle adenocarcinoma and lower incidence of prostate carcinomas in the Lobund-Wistar prostate cancer rat model using N-nitrosomethylurea and testosterone.
Tamano S; Rehm S; Waalkes MP; Ward JM
Vet Pathol; 1996 Sep; 33(5):557-67. PubMed ID: 8885183
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
16. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for advanced prostate cancer: Looking through new lenses.
Vogiatzi P; Cassone M; Claudio L; Claudio PP
Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
Semeniuk RC; Venner PM; North S
Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
[TBL] [Abstract][Full Text] [Related]
19. Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.
Pollard M; Luckert PH
Prostate; 1985; 6(1):1-5. PubMed ID: 3969369
[TBL] [Abstract][Full Text] [Related]
20. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
